Abstract
Background
In the present study we determined the antihyperalgesic and antiallodynic effect of celecoxib in diabetic rats as well as the possible participation of opioid receptors in the mechanism of action of celecoxib in these rats.
Methods
Experimental diabetes was induced by streptozotocin. Formalin (0.5%) was used to produce hyperalgesia in non-diabetic and diabetic rats. von Frey filaments were used to determine the 50% withdrawal threshold in diabetic rats.
Results
Oral administration of celecoxib (0.3–30 mg/kg) reduced formalin-induced nociceptive behavior during phase 2. Systemic pre-treatment (−10 min) with naltrexone (3 mg/kg) prevented celecoxib-induced antihyperalgesia in formalin-treated diabetic rats. Furthermore, naltrexone as well as the δ and κ opioid receptor antagonists naltrindole (3 mg/kg) and 5′-guanidino naltrindole (1 mg/kg), respectively, fully prevented celecoxib-induced antihyperalgesia (10 mg/kg) in formalin-treated non-diabetic and diabetic rats. Furthermore, celecoxib (0.3–30 mg/kg) produced an antiallodynic effect in diabetic rats. Pre-treatment with naltrexone (3 mg/kg) fully prevented the antiallodynic effect of celecoxib at 0.3, 3 and 10 mg/kg. In contrast, this dose of naltrexone only partially prevented the antiallodynic effect of celecoxib 30 mg/kg. Naltrexone and naltrindole (3 mg/kg), but not 5′-guanidino naltrindole (1 mg/kg), fully prevented the antiallodynic effect of celecoxib in diabetic rats.
Conclusions
Data suggest that celecoxib produces an antihyperalgesic and antiallodynic effect in diabetic rats. These effects seem to result from activation of μ, δ and κ opioid receptors for antinociception and μ and δ for antiallodynia. Celecoxib could be useful to treat neuropathic pain in diabetic patients.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Abbreviations
- ANOVA:
-
analysis of variance
- COX-2:
-
cyclo-oxygenase 2
- NSAIDs:
-
non-steroidal anti-inflammatory drugs
References
Galer BS, Gianas A, Jensen MP. Painful diabetic polyneuropathy: epidemiology, pain description, and quality of life. Diabetes Res Clin Pract 2000;47(2):123–8.
Sindrup SH, Jensen TS. Efficacy of pharmacological treatments of neuropathic pain: an update and effect related to mechanism of drug action. Pain 1999;83(3):389–400.
Morales-Vidal S, Morgan C, McCoyd M, Hornik A. Diabetic peripheral neuropathy and the management of diabetic peripheral neuropathic pain. Postgrad Med 2012;124(4):145–53.
Zhao Z, Chen SR, Eisenach JC, Busija DW, Pan HL. Spinal cyclooxygenase-2 is involved in development of allodynia after nerve injury in rats. Neuroscience 2000;97(4):743–8.
Hefferan MP, O’Rielly DD, Loomis CW. Inhibition of spinal prostaglandin synthesis early after L5/L6 nerve ligation prevents the development of prostaglandin-dependent and prostaglandin-independent allodynia in the rat. Anesthesiology 2003;99(5):1180–8.
Takahashi M, Kawaguchi M, Shimada K, Konishi N, Furuya H, Nakashima T. Cyclooxygenase-2 expression in Schwann cells and macrophages in the sciatic nerve after single spinal nerve injury in rats. Neurosci Lett 2004;363(3):203–6.
Padi SS, Kulkarni SK. Differential effects of naproxen and rofecoxib on the development of hypersensitivity following nerve injury in rats. Pharmacol Biochem Behav 2004;79(2):349–58.
Takahashi M, Kawaguchi M, Shimada K, Nakashima T, Furuya H. Systemic meloxicam reduces tactile allodynia development after L5 single spinal nerve injury in rats. Reg Anesth Pain Med 2005;30(4):351–5.
Courteix C, Bardin M, Chantelauze C, Lavarenne J, Eschalier A. Study of the sensitivity of the diabetes-induced pain model in rats to a range of analgesics. Pain 1994;57(2):153–60.
Schafers M, Marziniak M, Sorkin LS, Yaksh TL, Sommer C. Cyclooxygenase inhibition in nerve-injury- and TNF-induced hyperalgesia in the rat. Exp Neurol 2004;185(1):160–8.
Yamamoto H, Shimoshige Y, Yamaji T, Murai N, Aoki T, Matsuoka N. Pharmacological characterization of standard analgesics on mechanical allodynia in streptozotocin-induced diabetic rats. Neuropharmacology 2009;57(4):403–8.
Freshwater JD, Svensson CI, Malmberg AB, Calcutt NA. Elevated spinal cyclooxygenase and prostaglandin release during hyperalgesia in diabetic rats. Diabetes 2002;51(7):2249–55.
Ma W, Eisenach JC. Cyclooxygenase 2 in infiltrating inflammatory cells in injured nerve is universally up-regulated following various types of peripheral nerve injury. Neuroscience 2003;121(3):691–704.
Ma W, Chabot JG, Vercauteren F, Quirion R. Injured nerve-derived COX2/PGE2 contributes to the maintenance of neuropathic pain in aged rats. Neurobiol Aging 2010;31(7):1227–37.
Ramos KM, Jiang Y, Svensson CI, Calcutt NA. Pathogenesis of spinally mediated hyperalgesia in diabetes. Diabetes 2007;56(6):1569–76.
Suyama H, Kawamoto M, Gaus S, Yuge O. Effect of etodolac, a COX-2 inhibitor, on neuropathic pain in a rat model. Brain Res 2004;1010(1–2):144–50.
Bingham S, Beswick PJ, Bountra C, Brown T, Campbell IB, Chessell IP, et al. The cyclooxygenase-2 inhibitor GW406381X [2-(4-ethoxyphenyl)-3-[4-(methylsulfonyl)phenyl]-pyrazolo[1,5-bpyridazine] is effective in animal models of neuropathic pain and central sensitization. J Pharmacol Exp Ther 2005;312(3):1161–9.
Zhao FY, Spanswick D, Martindale JC, Reeve AJ, Chessell IP. GW406381, a novel COX-2 inhibitor, attenuates spontaneous ectopic discharge in sural nerves of rats following chronic constriction injury. Pain 2007;128(1–2):78–87.
Mi Y, Zhang X, Zhang F, Qi J, Gao H, Huang D, et al. The role of potassium channel activation in celecoxib-induced analgesic action. PLoS ONE 2013;8(1):e54797.
Matsunaga A, Kawamoto M, Shiraishi S, Yasuda T, Kajiyama S, Kurita S, et al. Intrathecally administered COX-2 but not COX-1 or COX-3 inhibitors attenuate streptozotocin-induced mechanical hyperalgesia in rats. Eur J Pharmacol 2007;554(1):12–7.
Kimura S, Kontani H. Demonstration of antiallodynic effects of the cyclooxygenase-2 inhibitor meloxicam on established diabetic neuropathic pain in mice. J Pharmacol Sci 2009;110(2):213–7.
Bermudez-Ocana DY, Aguilar-Mariscal H, Frias TR, Ble-Castillo JL, Flores-Murrieta FJ, Diaz-Zagoya JC, et al. Proglumide enhances the antinociceptive effect of cyclooxygenase inhibitors in diabetic rats in the formalin test. Eur J Pharmacol 2011;664(1–3):8–13.
Burian M, Geisslinger G. COX-dependent mechanisms involved in the anti-nociceptive action of NSAIDs at central and peripheral sites. Pharmacol Ther 2005;107(2):139–54.
Bovill JG. Mechanisms of actions of opioids and non-steroidal anti-inflammatory drugs. Eur J Anaesthesiol Suppl 1997;15:9–15.
Penning TD, Talley JJ, Bertenshaw SR, Carter JS, Collins PW, Docter S, et al. Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-ylbenze nesulfonamide (SC-58635, celecoxib). J Med Chem 1997;40(9):1347–65.
Rezende RM, Paiva-Lima P, Dos Reis WG, Camelo VM, Faraco A, Bakhle YS, et al. Endogenous opioid and cannabinoid mechanisms are involved in the analgesic effects of celecoxib in the central nervous system. Pharmacology 2012;89(3–4):127–36.
Rezende RM, Dos Reis WG, Duarte ID, Lima PP, Bakhle YS, de Francischi JN. The analgesic actions of centrally administered celecoxib are mediated by endogenous opioids. Pain 2009;142(1–2):94–100.
Correa JD, Paiva-Lima P, Rezende RM, Dos Reis WG, Ferreira-Alves DL, Bakhle YS, et al. Peripheral mu-, kappa- and delta-opioid receptors mediate the hypoalgesic effect of celecoxib in a rat model of thermal hyperalgesia. Life Sci 2010;86(25–26):951–6.
Bujalska M, Tatarkiewicz J, de Corde A, Gumulka SW. Effect of cyclooxygenase and nitric oxide synthase inhibitors on streptozotocin-induced hyperalgesia in rats. Pharmacology 2008;81(2):151–7.
Wagner K, Inceoglu B, Dong H, Yang J, Hwang SH, Jones P, et al. Comparative efficacy of 3 soluble epoxide hydrolase inhibitors in rat neuropathic and inflammatory pain models. Eur J Pharmacol 2013;700(1–3):93–101.
Zimmermann M. Ethical guidelines for investigations of experimental pain in conscious animals. Pain 1983;16(2):109–10.
Courteix C, Eschalier A, Lavarenne J. Streptozocin-induced diabetic rats: behavioural evidence for a model of chronic pain. Pain 1993;53(1):81–8.
Araiza-Saldana CI, Reyes-Garcia G, Bermudez-Ocana DY, Perez-Severiano F, Granados-Soto V. Effect of diabetes on the mechanisms of intrathecal anti-nociception of sildenafil in rats. Eur J Pharmacol 2005;527(1–3):60–70.
Juarez-Rojop IE, Granados-Soto V, Diaz-Zagoya JC, Flores-Murrieta FJ, Torres-Lopez JE. Involvement of cholecystokinin in peripheral nociceptive sensitization during diabetes in rats as revealed by the formalin response. Pain 2006;122(1–2):118–25.
Wheeler-Aceto H, Cowan A. Standardization of the rat paw formalin test for the evaluation of analgesics. Psychopharmacology 1991;104(1):35–44.
Dixon WJ. Efficient analysis of experimental observations. Annu Rev Pharmacol Toxicol 1980;20:441–62.
Chaplan SR, Bach FW, Pogrel JW, Chung JM, Yaksh TL. Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Methods 1994;53(1):55–63.
Arreola-Espino R, Urquiza-Marin H, Ambriz-Tututi M, Araiza-Saldana CI, Caram-Salas NL, Rocha-Gonzalez HI, et al. Melatonin reduces formalin-induced nociception and tactile allodynia in diabetic rats. Eur J Pharmacol 2007;577(1–3):203–10.
Gama KB, Quintans JS, Antoniolli AR, Quintans-Junior LJ, Santana WA, Branco A, et al. Evidence for the involvement of descending pain-inhibitory mechanisms in the antinociceptive effect of hecogenin acetate. J Natural Prod 2013;76(4):559–63.
Francischi JN, Chaves CT, Moura AC, Lima AS, Rocha OA, Ferreira-Alves DL, et al. Selective inhibitors of cyclo-oxygenase-2 (COX-2) induce hypoalgesia in a rat paw model of inflammation. Br J Pharmacol 2002;137(6):837–44.
Franca DS, Ferreira-Alves DL, Duarte ID, Ribeiro MC, Rezende RM, Bakhle YS, et al. Endogenous opioids mediate the hypoalgesia induced by selective inhibitors of cyclo-oxygenase 2 in rat paws treated with carrageenan. Neuropharmacology 2006;51(1):37–43.
Chopade AR, Sayyad FJ, Naikwade NS. Pharmacological characterization of carrageenan induced heat muscle hyperalgesia in rats using non-selective, preferential and selective COX-2 inhibitors. Pharmacol Rep 2014;66(3):353–62.
Nishiyama T. Analgesic effects of intrathecally administered celecoxib, a cyclooxygenase-2 inhibitor, in the tail flick test and the formalin test in rats. Acta Anaesthesiol Scand 2006;50(2):228–33.
Yamamoto T, Nozaki-Taguchi N. The role of cyclooxygenase-1 and -2 in the rat formalin test. Anesth Analg 2002;94(4):962–7.
Lu ZH, Xiong XY, Zhang BL, Lin GC, Shi YX, Liu ZG, et al. Evaluation of 2 celecoxib derivatives: analgesic effect and selectivity to cyclooxygenase-2/1. Acta Pharmacol Sin 2005;26(12):1505–11.
Rodrigues-Filho R, Campos MM, Ferreira J, Santos AR, Bertelli JA, Calixto JB. Pharmacological characterisation of the rat brachial plexus avulsion model of neuropathic pain. Brain Res 2004;1018(2):159–70.
Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000;284(10):1247–55.
Kellogg AP, Pop-Busui R. Peripheral nerve dysfunction in experimental diabetes is mediated by cyclooxygenase-2 and oxidative stress. Antioxid Redox Signal 2005;7(11–12):1521–9.
Du XN, Zhang X, Qi JL, An HL, Li JW, Wan YM, et al. Characteristics and molecular basis of celecoxib modulation on K(v)7 potassium channels. Br J Pharmacol 2011;164(6):1722–37.
Ortiz MI, Castañeda-Hernández G, Izquierdo-Vega JA, Sánchez-Gutiérrez M, Ponce-Monter HA, Granados-Soto V. Role of ATP-sensitive K+ channels in the antinociception induced by non-steroidal anti-inflammatory drugs in streptozotocin-diabetic and non-diabetic rats. Pharmacol Biochem Behav 2012;102(1):163–9.
Park SY, Kim TH, Kim HI, Shin YK, Lee CS, Park M, et al. Celecoxib inhibits Na+ currents in rat dorsal root ganglion neurons. Brain Res 2007;1148:53–61.
Frolov RV, Slaughter MM, Singh S. Effects of celecoxib on ionic currents and spontaneous firing in rat retinal neurons. Neuroscience 2008;154(4):1525–32.
Ma W, Quirion R. Does COX2-dependent PGE2 play a role in neuropathic pain? Neurosci Lett 2008;437(3):165–9.
Dong XW, Goregoaker S, Engler H, Zhou X, Mark L, Crona J, et al. Small interfering RNA-mediated selective knockdown of Na(V)1.8 tetrodotoxinresistant sodium channel reverses mechanical allodynia in neuropathic rats. Neuroscience 2007;146(2):812–21.
Cheng KI, Lai CS, Wang FY, Wang HC, Chang LL, Ho ST, et al. Intrathecal lidocaine pretreatment attenuates immediate neuropathic pain by modulating Nav1.3 expression and decreasing spinal microglial activation.BMC Neurol 2011;11:71.
Mixcoatl-Zecuatl T, Aguirre-Banuelos P, Granados-Soto V. Sildenafil produces antinociception and increases morphine antinociception in the formalin test. Eur J Pharmacol 2000;400(1):81–7.
Lashbrook JM, Ossipov MH, Hunter JC, Raffa RB, Tallarida RJ, Porreca F. Synergistic antiallodynic effects of spinal morphine with ketorolac and selective COX1- and COX2-inhibitors in nerve-injured rats. Pain 1999;82(1):65–72.
Ortega-Varela LF, Herrera JE, Caram-Salas NL, Rocha-Gonzalez HI, Torres-Lopez JE, Granados-Soto V. Synergistic antiallodynic interaction of the metamizol-gabapentin combination. Drug Dev Res 2009;70:386–94.
Strichartz GR, Zhou Z, Sinnott C, Khodorova A. Therapeutic concentrations of local anaesthetics unveil the potential role of sodium channels in neuropathic pain. Novartis Found Symp 2002;241:189–201.
Dickenson AH, Sullivan AF. Peripheral origins and central modulation of subcutaneous formalin-induced activity of rat dorsal horn neurones. Neurosci Lett 1987;83(1–2):207–11.
Bierhaus A, Fleming T, Stoyanov S, Leffler A, Babes A, Neacsu C, et al. Methylglyoxal modification of Nav1.8 facilitates nociceptive neuron firing and causes hyperalgesia in diabetic neuropathy. Nat Med 2012;18(9):1445.
Calcutt NA. Location, location, location?: is the pain of diabetic neuropathy generated by hyperactive sensory neurons? Diabetes 2013;62(11):3658–60.
Bingham S, Beswick PJ, Bountra C, Brown T, Campbell IB, Chessell IP, et al. The cyclooxygenase-2 inhibitor GW406381X [2-(4-ethoxyphenyl)-3-[4-(methylsulfonyl)phenyl-]pyrazolo[1,5-bpyridazine] is effective in animal models of neuropathic pain and central sensitization. J Pharmacol Exp Ther 2005; 312(3):1161–9.
Chichorro JG, Zampronio AR, Souza GE, Rae GA. Orofacial cold hyperalgesia due to infraorbital nerve constriction injury in rats: reversal by endothelin receptor antagonists but not non-steroidal anti-inflammatory drugs. Pain 2006;123(1–2):64–74.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Juárez-Rojop, I.E., Morales-Hernández, P.E., Tovilla-Zárate, C.A. et al. Celecoxib reduces hyperalgesia and tactile allodynia in diabetic rats. Pharmacol. Rep 67, 545–552 (2015). https://doi.org/10.1016/j.pharep.2014.12.006
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1016/j.pharep.2014.12.006